PMID- 31747910
OWN - NLM
STAT- MEDLINE
DCOM- 20200121
LR  - 20200121
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 19
IP  - 1
DP  - 2019 Nov 20
TI  - Inhibitory effects of ChondroT and its constituent herbs on RANKL-induced 
      osteoclastogenesis.
PG  - 319
LID - 10.1186/s12906-019-2737-8 [doi]
LID - 319
AB  - BACKGROUND: ChondroT is a complex herbal medicine consisting of water extracts of 
      Ostericum koreanum (Maxim.) Kitag., Lonicera japonica Thunb., Angelica gigas 
      Nakai, Clematis manshurica Rupr., and Phellodendron amurense Rupr. (6:4:4:4:3). 
      Previous studies have reported that ChondroT possesses chondroprotective and 
      anti-inflammatory, anti-osteoarthritic, and anti-hyperuricemic activities. The 
      study is aim to demonstrate the effects of ChondroT and its five constituent 
      herbs on receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis 
      and the underlying mechanisms. METHODS: Osteoclastogenesis was identified in bone 
      marrow-derived macrophages (BMDMs) by tartrate-resistant acid phosphatase (TRAP) 
      staining assay, actin ring formation assay and the bone resorption assay. For the 
      molecular mechanisms, activation of RANKL-induced NF-kappaB and MAPK signaling 
      pathways and the expression levels of osteoclast-specific proteins were 
      investigated by Western blotting. Cell viability was assessed by MTT assay. Actin 
      ring formation and NF-kappaB translocation were evaluated by immunostaining. RESULTS: 
      ChondroT and each of its constituent herbs significantly suppressed osteoclast 
      differentiation dose dependently, and decreased actin ring formation as well as 
      bone-resorbing capacity. Mechanistically, ChondroT and its constituent herbs 
      downregulated the expressional levels of osteoclast-specific proteins such as 
      NFATc1, c-Fos, Cathepsin K, and matrix metalloproteinase 9 (MMP9) by suppressing 
      NF-kappaB translocation to nucleus and MAPKs phosphorylation at different levels. 
      Compared to its five constituent herbs, ChondroT exhibited the best inhibitory 
      efficiency against osteoclastogenesis. CONCLUSIONS: Taken together, ChondroT has 
      anti-osteoclastogenesis properties by inhibiting NF-kappaB and MAPKs pathways. It 
      could be considered as a potential therapeutic candidate for the treatment of 
      osteoclast-related bone diseases.
FAU - Guo, Rui Hong
AU  - Guo RH
AD  - College of Pharmacy and Research Institute of Drug Development, Chonnam National 
      University, Gwangju, 500-757, Republic of Korea.
FAU - Kim, Seon-Jong
AU  - Kim SJ
AD  - College of Korean Medicine, Dongshin University, 185 Geonjae-ro, Naju-si, 
      Jeollanam-do, 58245, Republic of Korea.
FAU - Choi, Chan-Hun
AU  - Choi CH
AD  - College of Korean Medicine, Dongshin University, 185 Geonjae-ro, Naju-si, 
      Jeollanam-do, 58245, Republic of Korea.
FAU - Na, Chang-Su
AU  - Na CS
AD  - College of Korean Medicine, Dongshin University, 185 Geonjae-ro, Naju-si, 
      Jeollanam-do, 58245, Republic of Korea.
FAU - Kang, Bok Yun
AU  - Kang BY
AD  - College of Pharmacy and Research Institute of Drug Development, Chonnam National 
      University, Gwangju, 500-757, Republic of Korea.
FAU - Kim, Young Ran
AU  - Kim YR
AD  - College of Pharmacy and Research Institute of Drug Development, Chonnam National 
      University, Gwangju, 500-757, Republic of Korea. kimyr@chonnam.ac.kr.
LA  - eng
GR  - HI17C0911/Korea Health Industry Development Institute/Republic of Korea
PT  - Journal Article
DEP - 20191120
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
RN  - 0 (Plant Preparations)
RN  - 0 (RANK Ligand)
SB  - IM
MH  - Animals
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Osteoclasts/*drug effects
MH  - Osteogenesis/*drug effects
MH  - Plant Preparations/*pharmacology
MH  - RANK Ligand/*pharmacology
PMC - PMC6864957
OTO - NOTNLM
OT  - Bone resorption
OT  - ChondroT
OT  - MAPKs
OT  - NF-kappaB
OT  - Osteoclast
COIS- The authors declare that they have no competing interests.
EDAT- 2019/11/22 06:00
MHDA- 2020/01/22 06:00
PMCR- 2019/11/20
CRDT- 2019/11/22 06:00
PHST- 2019/06/07 00:00 [received]
PHST- 2019/10/31 00:00 [accepted]
PHST- 2019/11/22 06:00 [entrez]
PHST- 2019/11/22 06:00 [pubmed]
PHST- 2020/01/22 06:00 [medline]
PHST- 2019/11/20 00:00 [pmc-release]
AID - 10.1186/s12906-019-2737-8 [pii]
AID - 2737 [pii]
AID - 10.1186/s12906-019-2737-8 [doi]
PST - epublish
SO  - BMC Complement Altern Med. 2019 Nov 20;19(1):319. doi: 10.1186/s12906-019-2737-8.